Q-omics provides the consensus-scored PMEPA1 profile across patient tissues and cancer cell-line models. PMEPA1 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, PMEPA1 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, PMEPA1 RNA expression shows 17,478 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and HNSC as cancer lineages where PMEPA1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PMEPA1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PMEPA1 survival associations across molecular data types. PMEPA1 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (7) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PMEPA1 RNA expression–survival associations across cancer types. High PMEPA1 expression shows unfavorable associations in UVM, CESC, LUSC, HNSC, KIRP and LUAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for PMEPA1 RNA expression.
This table summarizes PMEPA1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for PMEPA1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PMEPA1 shows higher tumor expression in HNSC, KIRC, COAD, BLCA, STAD and LUAD. The HNSC box plot shows higher PMEPA1 RNA expression in tumor versus normal tissue (log2 FC = +3.068, t-test p < 0.001).
This table shows molecular features associated with PMEPA1 in patient tissues and cancer cell lines. In patient samples, PMEPA1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PMEPA1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SKIN.
